Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Get an introduction to all features of this page
Price
Target price
€0.34

€0.34

1.500%
-0.01
1.500%
€2.35

€2.35

 
Latest predictions
€2.00
04.06.19
buy
€2.70
09.03.19
buy
€1.50
01.03.19
buy
€4.50
02.10.18
buy
Your prediction

aap Implantate AG Stock

aap Implantate AG gained 1.500% today.
Our community is currently high on aap Implantate AG with 4 Buy predictions and 0 Sell predictions.
Based on the current price of €0.34 the target price of €2.00 shows a potential of 497.015% for aap Implantate AG which would more than double the current price.

Pros and Cons of aap Implantate AG in the next few years

Pros
?
Future proof business model
?
Growth compared to competition
?
Brand
Cons
?
Conscious of the environment
?
Market Position
?
Non-cyclic/Cyclic
Tell us your opinion to access the 'Wisdom of the Crowds'

Comments

Buy aap Implantate AG

Show more
You may not comment on this article as you either did not confirm your account yet or were blocked. If you think this is a mistake please contact us. Show more

Other discussions about aap Implantate AG Stock

Trading aap Implantate AG

Trading aap Implantate AG

New thread Forum

News

DGAP-Adhoc: aap Implantate AG offers its shareholders a convertible bond with a total nominal value of EUR 2.6 million; attractive offer and a major step toward securing the company's continued existence

DGAP-Adhoc: aap Implantate AG offers its shareholders a convertible bond with a total nominal value of EUR 2.6 million; attractive offer and a major step toward securing the company's continued existence

DGAP-News: Sales Q2/2020 and H1/2020: Continued dynamic development in the U.S. with double-digit growth rates; international and German business strongly impacted by COVID-19 pandemic

DGAP-News: Sales Q2/2020 and H1/2020: Continued dynamic development in the U.S. with double-digit growth rates; international and German business strongly impacted by COVID-19 pandemic

DGAP-News: Annual financial statements 2019: 9% sales growth and strongly improved EBITDA; significant milestones and growing interest in pioneering key technologies antibacterial silver coating and resorbable magnesium implants

DGAP-News: Annual financial statements 2019: 9% sales growth and strongly improved EBITDA; significant milestones and growing interest in pioneering key technologies antibacterial silver coating and resorbable magnesium implants

DGAP-Adhoc: aap Implantate AG: Refusal of audit opinions for annual financial report 2019 (HGB) and consolidated annual financial report 2019 (IFRS); implementation of various financing and cost-saving options to secure financing

DGAP-Adhoc: aap Implantate AG: Refusal of audit opinions for annual financial report 2019 (HGB) and consolidated annual financial report 2019 (IFRS); implementation of various financing and cost-saving options to secure financing

DGAP-News: aap Implantate AG: Postponement of publication of annual financial statements 2019 and annual general meeting 2020

DGAP-News: aap Implantate AG: Postponement of publication of annual financial statements 2019 and annual general meeting 2020

DGAP-News: aap receives approval from ethics commissions for human clinical study for innovative antibacterial silver coating technology; all regulatory requirements for starting study in Germany fulfilled

DGAP-News: aap receives approval from ethics commissions for human clinical study for innovative antibacterial silver coating technology; all regulatory requirements for starting study in Germany fulfilled

DGAP-Adhoc: aap Implantate AG resolves on concept for extensive staff reduction and extraordinary value adjustment to capitalized development costs; postponement of publication of the 2019 financial statements

DGAP-Adhoc: aap Implantate AG resolves on concept for extensive staff reduction and extraordinary value adjustment to capitalized development costs; postponement of publication of the 2019 financial statements